{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:30:57Z","timestamp":1761093057639,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FRN-408093"],"award-info":[{"award-number":["FRN-408093"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.urolonc.2022.03.019","type":"journal-article","created":{"date-parts":[[2022,5,8]],"date-time":"2022-05-08T23:34:03Z","timestamp":1652052843000},"page":"343.e1-343.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Salvage partial gland ablation for recurrent prostate cancer following primary partial gland ablation: Functional and oncological outcomes"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6106-3123","authenticated-orcid":false,"given":"Yazan","family":"Qaoud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime O.","family":"Herrera-Caceres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Bass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad Baker","family":"Berjaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miran","family":"Kenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Lajkosz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Finelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Perlis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.urolonc.2022.03.019_bib0001","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.euo.2020.12.008","article-title":"A systematic review of focal ablative therapy for clinically localised prostate cancer in comparison with standard management options: limitations of the available evidence and recommendations for clinical practice and further research","volume":"4","author":"Bates","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2022.03.019_bib0002","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eururo.2018.06.006","article-title":"A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer","volume":"74","author":"Guillaumier","year":"2018","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.03.019_bib0003","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2016.08.044","article-title":"New and established technology in focal ablation of the prostate: a systematic review","volume":"71","author":"Valerio","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2022.03.019_bib0004","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.eururo.2013.05.048","article-title":"The role of focal therapy in the management of localised prostate cancer: a systematic review","volume":"66","author":"Valerio","year":"2014","journal-title":"Eur Urol"},{"issue":"203","key":"10.1016\/j.urolonc.2022.03.019_bib0005","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/JU.0000000000000506","article-title":"Focal therapy for localized prostate cancer with either high intensity focused ultrasound or cryoablation: a single institution experience","volume":"203","author":"Tourinho-Barbosa","year":"2020","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2022.03.019_bib0006","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bju.14976","article-title":"Salvage radical prostatectomy following focal therapy: functional and oncological outcomes","volume":"125","author":"Herrera-Caceres","year":"2020","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.urolonc.2022.03.019_bib0007","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.euo.2019.03.008","article-title":"Salvage local treatments after focal therapy for prostate cancer","volume":"2","author":"Marra","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2022.03.019_bib0008","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bju.15004","article-title":"Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry","volume":"125","author":"Lovegrove","year":"2020","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.urolonc.2022.03.019_bib0009","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.juro.2018.07.040","article-title":"Oncologic and functional outcomes of partial gland ablation with high intensity focused ultrasound for localized prostate cancer","volume":"201","author":"Bass","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2022.03.019_bib0010","article-title":"What are the limits of focal therapy for localized prostate cancer? For: GG3-5 may be considered","author":"Perlis","year":"2019","journal-title":"Eur Urol Focus."},{"issue":"4","key":"10.1016\/j.urolonc.2022.03.019_bib0011","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.urolonc.2022.03.019_bib0012","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11255-014-0887-7","article-title":"Salvage cryosurgery for locally recurrent prostate cancer after primary cryotherapy","volume":"47","author":"Chang","year":"2015","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"10.1016\/j.urolonc.2022.03.019_bib0013","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.juro.2013.12.036","article-title":"Morbidity associated with primary high intensity focused ultrasound and redo high intensity focused ultrasound for localized prostate cancer","volume":"191","author":"Berge","year":"2014","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2022.03.019_bib0014","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00345-006-0107-x","article-title":"Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer","volume":"24","author":"Blana","year":"2006","journal-title":"World J Urol"},{"issue":"21","key":"10.1016\/j.urolonc.2022.03.019_bib0015","first-page":"00114-0","article-title":"Long-term outcomes of focal cryotherapy for low- to intermediate-risk prostate cancer: results and matched pair analysis with active surveillance [published online ahead of print, 2021 Apr 26]","volume":"S2405-4569","author":"Marra","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.urolonc.2022.03.019_bib0016","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.juro.2017.07.070","article-title":"Prostate specific membrane antigen targeted 18F-DCFPyL positron emission tomography\/computerized tomography for the preoperative staging of high risk prostate cancer: results of a prospective, phase II, single center study","volume":"199","author":"Gorin","year":"2018","journal-title":"J Urol"},{"issue":"30","key":"10.1016\/j.urolonc.2022.03.019_bib0017","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1200\/JCO.2015.62.5764","article-title":"Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer","volume":"33","author":"Tosoian","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922001090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922001090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:25:11Z","timestamp":1761042311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143922001090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1078143922001090"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.03.019","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salvage partial gland ablation for recurrent prostate cancer following primary partial gland ablation: Functional and oncological outcomes","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}